TiumBio Co., Ltd. (KOSDAQ: 321550) presented interim data from a Phase 2a trial of tosposertib combined with pembrolizumab for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE